Supplementary Material

**eReferences (supplemental material online):**

e20. Behre HM, Kliesch S, Schadel F, Nieschlag E. Clinical relevance of scrotal and transrectal ultrasonography in andrological patients. Int J Androl. 1995 Dec;18 Suppl 2:27-31.

e21. Raman JD, Nobert CF, Goldstein M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. J Urol. 2005 Nov;174(5):1819-22; discussion 22.

e22. Dieckmann KP, Hartmann JT, Classen J, Ludde R, Diederichs M, Pichlmeier U. Tallness is associated with risk of testicular cancer: evidence for the nutrition hypothesis. Br J Cancer. 2008 Nov 04;99(9):1517-21.

e23. Lerro CC, McGlynn KA, Cook MB. A systematic review and meta-analysis of the relationship between body size and testicular cancer. Br J Cancer. 2010 Oct 26;103(9):1467-74.

e24. Latif T, Kold Jensen T, Mehlsen J, Holmboe SA, Brinth L, Pors K, et al. Semen quality as a predictor of subsequent morbidity: a Danish cohort study of 4,712 men with long-term follow-up. Am J Epidemiol. 2017 Oct 15;186(8):910-17.

e25. Olesen IA, Andersson AM, Aksglaede L, Skakkebaek NE, Rajpert-de Meyts E, Joergensen N, et al. Clinical, genetic, biochemical, and testicular biopsy findings among 1,213 men evaluated for infertility. Fertil Steril. 2017 Jan;107(1):74-82.e7.

e26. Ilic D, Misso ML. Screening for testicular cancer. Cochrane Database Syst Rev. 2011 Feb 16(2):16;(2):CD007853.

e27. USPSTF. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Annals of internal medicine. 2011 Apr 05;154(7):483-6.

e28. EAU. EAU Guidelines on Testicular Cancer. In: P. Albers (Chair), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, et al., editors.: European Association of Urology; 2018a.

e29. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. European urology. 2016 Jul;70(1):93-105.

e30. KCE. Tombal, B., Vlayen, J., Stordeur, S., De Meerleer, G., Gil, T., Renard, L., Rorive, S., Rottey, S., Salmon, I., Schrijvers, D., Villeirs, G. Wetenschappelijke ondersteuning van het College voor Oncologie: een update van de nationale richtlijn voor testiskanker [Internet]. 2010 2016 October 28. Available from: <https://kce.fgov.be/sites/default/files/atoms/files/kce_142a_richtlijnen_testiskanker_1.pdf>

e31. SIGN. Management of adult testicular germ cell tumours. A national clinical guideline. Edinburgh, (Scotland): Scottish Intercollegiate Guidelines Network (SIGN). 2011;SIGN publication; no. 124:63.

e32. Zhao JY, Ma XL, Li YY, Zhang BL, Li MM, Ma XL, et al. Diagnostic accuracy of 18F-FDG-PET in patients with testicular cancer: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(8):3525-31.

e33. ESMO. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. In: Oldenburg J, Fossa SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, et al., editors. 2013/10/23 ed. Ann Oncol2013. p. vi125-32.

e34. Dieckmann KP, Kulejewski M, Pichlmeier U, Loy V. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. European urology. 2007 Jan;51(1):175-83; discussion 83-5.

e35. Tan IB, Ang KK, Ching BC, Mohan C, Toh CK, Tan MH. Testicular microlithiasis predicts concurrent testicular germ cell tumors and intratubular germ cell neoplasia of unclassified type in adults: a meta-analysis and systematic review. Cancer. 2010 Jun 24;116(19):4520-32.

e36. DGGG, DGU, DGRM. Fertility preservation for patients with malignant disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No. 015/082. <http://www.awmf.org/uploads/tx_szleitlinien/015-082l_S2k_Fertilitaetserhaltung-bei-onkologischen-Therapien_2017-12.pdf> (Zugriff am 12.12.2017). DKG Eigenverlag. 2017.

e37. Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 1;33(1):51-7.

e38. Kier MG, Lauritsen J, Mortensen MS, Bandak M, Andersen KK, Hansen MK, et al. Prognostic factors and treatment results after bleomycin, etoposide, and cisplatin in germ cell cancer: a population-based study. European urology. 2017 Feb;71(2):290-98.

e39. Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Apr 15;21(8):1505-12.

e40. Nicolai N, Miceli R, Necchi A, Biasoni D, Catanzaro M, Milani A, et al. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. European urology. 2010 Dec;58(6):912-8.

e41. Williams SB, Kacker R, Winston D, Bahnson E, Steele GS, Richie JP. Predictors of positive retroperitoneal lymph nodes in patients with high risk testicular cancer. J Urol. 2011 Dec;186(6):2245-8.

e42. Dong P, Liu ZW, Li XD, Li YH, Yao K, Wu S, et al. Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors. Med Oncol. 2013 Mar;30(1):494.

e43. Daugaard G, Gundgaard MG, Mortensen MS, Agerbaek M, Holm NV, Rorth M, et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Dec 1;32(34):3817-23.

e44. Howard SA, Gray KP, O'Donnell EK, Fennessy FM, Beard CJ, Sweeney CJ. Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor. AJR Am J Roentgenol. 2014 Oct;203(4):W415-20.

e45. Li X, Guo S, Wu Z, Dong P, Li Y, Zhang Z, et al. Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors. World J Urol. 2015 Sep;33(9):1351-7.

e46. Zengerling F, Kunath F, Jensen K, Ruf C, Schmidt S, Spek A. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance - a systematic review. Urologic oncology. 2017 Jul 13;pii: S1078-1439(17)30331-9.

e47. Lo KC, Wong C, Emond J, Aprikian AG. Scrotal orchiectomy for a large testicular seminoma. Can J Urol. 2001 Apr;8(2):1234-6.

e48. Herrinton LJ, Brox T, Greenland S, Finkle WD, Cattolica E, Shoor S. Regarding: a cohort study of systemic and local complications following implantation of testicular prostheses. Ann Epidemiol. 2003 Jan;13(1):73-7.

e49. Dieckmann KP. Contralateral biopsies in patients with testicular germ-cell tumour-nuisance or new sense? Ann Oncol. 2015a Apr;26(4):620-1.

e50. Robinson R, Tait CD, Clarke NW, Ramani VA. Is it safe to insert a testicular prosthesis at the time of radical orchidectomy for testis cancer: an audit of 904 men undergoing radical orchidectomy. BJU Int. 2016 Feb;117(2):249-52.

e51. Lipworth L, Tarone RE, McLaughlin JK. Silicone breast implants and connective tissue disease: an updated review of the epidemiologic evidence. Ann Plast Surg. 2004 Jun;52(6):598-601.

e52. Balk EM, Earley A, Avendano EA, Raman G. Long-term health outcomes in women with silicone gel breast implants: a systematic review. Annals of internal medicine. 2016 Feb 2;164(3):164-75.

e53. Bang AK, Petersen JH, Petersen PM, Andersson AM, Daugaard G, Jørgensen N. Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells. Int J Radiat Oncol Biol Phys. 2009;75(3):672-76.

e54. Dieckmann KP, Anheuser P, Sattler F, Von Kügelgen T, Matthies C, Ruf CG. Sequential bilateral testicular tumours presenting with intervals of 20 years and more. BMC Urol. 2013a;13(1):71.

e55. Brabrand S, Fosså SD, Cvancarova M, Axcrona U, Lehne G. Probability of metachronous testicular cancer in patients with biopsy-proven intratubular germ cell neoplasia depends on first-time treatment of germ cell cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(32):4004-10.

e56. Detti B, Scoccianti S, Villari D, Cipressi S, Sardaro A, Simontacchi G, et al. Management of stage l testicular seminoma over a period of 49 years. Onkologie. 2011;34(10):510-4.

e57. Kollmannsberger C, Tyldesley S, Moore C, Chi KN, Murray N, Daneshmand S, et al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol. 2011 Apr;22(4):808-14.

e58. Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian Testicular Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Feb 20;29(6):719-25.

e59. Haugnes HS, Solhaug O, Stenberg J, Hjelle LV, Bremnes RM. Seminoma patients treated at a minor oncological department during 1986-2010: treatment and outcome. Anticancer Res. 2014 Aug;34(8):4253-60.

e60. Soper MS, Hastings JR, Cosmatos HA, Slezak JM, Wang R, Lodin K. Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma: clinical outcomes and prognostic factors for relapse in a large US cohort. Am J Clin Oncol. 2014 Aug;37(4):356-9.

e61. Chau C, Cathomas R, Wheater M, Klingbiel D, Fehr M, Bennett J, et al. Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience. Ann Oncol. 2015 Sep;26(9):1865-70.

e62. Serdar L, Canyilmaz E, Topcu TO, Sahbaz A, Memis Y, Soydemir G, et al. Adjuvant radiotherapy in stage 1 seminoma: Evaluation of prognostic factors and results of survival. J Cancer Res Ther. 2015 Apr-Jun;11(2):313-8.

e63. Tandstad T, Stahl O, Hakansson U, Wahlqvist R, Klepp O, Cavallin-Stahl E, et al. The SWENOTECA group: A good example of continuous binational and multidisciplinary collaboration for patients with testicular cancer in Sweden and Norway. Scand J Urol. 2016;50(1):9-13.

e64. Cummins S, Yau T, Huddart R, Dearnaley D, Horwich A. Surveillance in stage I seminoma patients: a long-term assessment. European urology. 2010 Apr;57(4):673-8.

e65. Kamba T, Kamoto T, Okubo K, Teramukai S, Kakehi Y, Matsuda T, et al. Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients. Int J Urol. 2010 Dec;17(12):980-7.

e66. Leung E, Warde P, Jewett M, Panzarella T, O'Malley M, Sweet J, et al. Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy. BJU Int. 2013 Dec;112(8):1088-95.

e67. Mortensen MS, Lauritsen J, Gundgaard MG, Agerbaek M, Holm NV, Christensen IJ, et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. European urology. 2014 Dec;66(6):1172-8.

e68. Aparicio J, Maroto P, del Muro XG, Guma J, Sanchez-Munoz A, Margeli M, et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Dec 10;29(35):4677-81.

e69. Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1992 Nov;10(11):1762-8.

e70. Oliver RT, Ong J, Shamash J, Ravi R, Nagund V, Harper P, et al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology. 2004 Mar;63(3):556-61.

e71. Maroto P, Garcia del Muro X, Aparicio J, Paz-Ares L, Arranz JA, Guma J, et al. Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. Ann Oncol. 2005 Dec;16(12):1915-20.

e72. Ondrus D, Kajo K, Stastna V, Ondrusova M. Controversies in the management of clinical stage I nonseminomatous germ cell testicular cancer. Klin Onkol. 2015;28(2):112-5.

e73. Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Jun 20;26(18):2966-72.

e74. Tandstad T, Stahl O, Hakansson U, Dahl O, Haugnes HS, Klepp OH, et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol. 2014 Nov;25(11):2167-72.